Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership
Executive Summary
You may also be interested in...
Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS
A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).
Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Need a specific report? 1000+ reports available
Buy Reports